Casazza A M, Savi G, Pratesi G, Di Marco A
Eur J Cancer Clin Oncol. 1983 Mar;19(3):411-8. doi: 10.1016/0277-5379(83)90140-2.
4'-Deoxydoxorubicin has been compared with doxorubicin as regards potency, antitumor activity and toxicity in tumored and non-tumored mice treated i.v. according to different schedules. 4'-Deoxydoxorubicin was 1.5-3 times more toxic and more potent than doxorubicin. At equitoxic doses, 4'-deoxydoxorubicin was: as active as doxorubicin against Gross leukemia, mammary carcinoma and MS-2 sarcoma; slightly less active than doxorubicin against B16 melanoma; more active than doxorubicin against colon 38 adenocarcinoma. The best schedule of administration of 4'-deoxydoxorubicin in mice was the weekly treatment. The strong effectiveness against colon 38 adenocarcinoma makes 4'-deoxydoxorubicin a particularly interesting new anthracycline derivative that deserves clinical trials.
已根据不同给药方案，对接受静脉注射的荷瘤和未荷瘤小鼠，就4'-脱氧阿霉素与阿霉素的效力、抗肿瘤活性和毒性进行了比较。4'-脱氧阿霉素的毒性比阿霉素高1.5至3倍，效力也更强。在等毒性剂量下，4'-脱氧阿霉素：对白血病、乳腺癌和MS-2肉瘤的活性与阿霉素相当；对B16黑色素瘤的活性略低于阿霉素；对结肠38腺癌的活性高于阿霉素。小鼠中4'-脱氧阿霉素的最佳给药方案是每周治疗。4'-脱氧阿霉素对结肠38腺癌的强效作用使其成为一种特别引人关注的新型蒽环类衍生物，值得进行临床试验。
Zotero 插件